This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schroeder, J. R. Articles by Armenian, H. K. Search for Related Content PubMed PubMed Citation Articles by Schroeder, J. R. Articles by Armenian, H. K.

Serum Soluble CD23 Level Correlates with Subsequent Development of AIDS-related Non-Hodgkin’s Lymphoma¹

Departments of Epidemiology [J. R. S., A. J. S., L. P. J., H. K. A.], Molecular Microbiology and Immunology [J. B. M.], and Oncology [R. F. A.], Johns Hopkins University Baltimore, Maryland 21205; Department of Statistics and Institute for Aging, Health, and Health Care Policy, Rutgers University, New Brunswick, New Jersey 08901 [D. R. H.]; Departments of Obstetrics and Gynecology [O. M-M., E. C. B.] and Microbiology, Immunology, and Molecular Genetics [O. M-M., E. C. B.], University of California at Los Angeles, Los Angeles, California 90095; Department of Pathology, Northwestern University [D. V.]; and Department of Infectious Diseases and Microbiology, University of Pittsburgh, Pittsburgh, Pennsylvania 15261 [D. T. R.]

The cytokine soluble CD23 (sCD23) has been shown to act as a B cell growth factor and to be elevated in serum prior to development of AIDS-related non-Hodgkin’s lymphoma (AIDS NHL). To further characterize the elevation of serum sCD23 in AIDS NHL patients and investigate its potential as a diagnostic test, a matched case-control study of AIDS NHL (n = 101) was nested within the Multicenter AIDS Cohort Study. Serum sCD23 was measured in cases’ and controls’ serum specimens at three different time periods (0–6, 6–12, and 12–18 months) and CD4+ thresholds (0–99, 100–199, and 200–299 cells/µl) prior to the case’s NHL diagnosis. Changes in serum sCD23 over time were examined in AIDS NHL cases relative to controls, and t tests were performed to determine whether cases’ serum sCD23 exceeded that of controls at each time period and CD4+ threshold. Overall, cases’ median serum sCD23 levels were approximately double those of controls. Serum sCD23 concentration was positively correlated with lymphocyte counts for both cases and controls. The difference in cases’ and controls’ serum sCD23 levels became greater as AIDS NHL diagnosis date approached: in the 18 months preceding the case’s NHL diagnosis, serum sCD23 was stable in cases but dropped in controls. Although this difference was statistically significant (P < 0.05), it was not clinically significant. It is unlikely that serum sCD23 would make a useful test for AIDS NHL because the magnitude of the difference between cases and controls was small and there was no change in serum sCD23 in cases that would indicate disease.

This article has been cited by other articles:

				M. P. Purdue, Q. Lan, A. Kricker, A. E. Grulich, C. M. Vajdic, J. Turner, D. Whitby, S. Chanock, N. Rothman, and B. K. Armstrong Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: findings from the New South Wales non-Hodgkin Lymphoma Study Carcinogenesis, March 1, 2007; 28(3): 704 - 712. [Abstract] [Full Text] [PDF]

				A. E. Grulich, C. M. Vajdic, J. M. Kaldor, A. M. Hughes, A. Kricker, L. Fritschi, J. J. Turner, S. Milliken, G. Benke, and B. K. Armstrong Birth Order, Atopy, and Risk of Non-Hodgkin Lymphoma J Natl Cancer Inst, April 20, 2005; 97(8): 587 - 594. [Abstract] [Full Text] [PDF]

				B. M. Birmann, N. Mueller, A. Okayama, C.-C. Hsieh, N. Tachibana, H. Tsubouchi, E. T. Lennette, D. Harn, and S. Stuver Serologic Assessment of Type 1 and Type 2 Immunity in Healthy Japanese Adults Cancer Epidemiol. Biomarkers Prev., August 1, 2004; 13(8): 1385 - 1391. [Abstract] [Full Text] [PDF]